Celleron Therapeutics and Argonaut Therapeutics, both University of Oxford spinout companies, have recently announced the completion of a merger to form IngenOx Therapeutics.
International legal practice Osborne Clarke advised Argonaut Therapeutics, a preclinical-stage biotech company focusing on the research and discovery of new epigenetic drugs against unmet cancers, on its merger with Celleron Therapeutics, a clinical-stage biopharmaceutical company advancing a pipeline of precision medicine drugs for advanced cancer indications.
Combining both clinical stage programmes and a research pipeline, IngenOx Therapeutics will focus on delivering new precision medicine drugs and vaccines to treat the most difficult cancers, often referred to as cold tumours.
Supported by Oxford Science Enterprises, the merger of the two University of Oxford spinout companies brings together drug discovery and clinical development capabilities, which will streamline the R&D process and ensures pipeline continuity.
Osborne Clarke's team was led by Partner Justin Starling and Associate Director Elizabeth Yell.
Osborne Clarke’s Corporate team is considered a go-to practice for many companies in the life sciences and healthcare sector. The team advises at every stage of company development across all corporate issues, from equity and debt fundraisings to M&A, IPOs and JVs.